New AMA Category III CPT Code Issued for Transcatheter Removal/Debulking of Intracardiac Masses
Latham, New York, August 24, 2021 – AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, applauds the work of the Society of Thoracic Surgeons (STS) to champion the creation of a new Category III CPT code approved by the American Medical Association (AMA) CPT Panel.
CPT code 0644T (transcatheter removal or debulking of intracardiac mass [e.g. vegetations, thrombus] via suction [e.g. vacuum, aspiration] device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed) gives physicians an updated billing code for use with procedures utilizing catheter-assisted technology such as AngioDynamics’ AngioVac System for removal of undesirable intravascular material in the right heart.
The new code, which became effective in July 2021, reflects the growing use of minimally invasive technology such as the AngioVac System by physicians for percutaneous access and removal of intracardiac masses.
“The STS requested this Category III code, 0644T, specifically to capture the physician work and frequency for innovative and important therapies like the AngioVac System,” said Seenu Reddy, MD,1 Cardiovascular Surgeon and the Director of Cardiovascular Surgery for Centennial Heart and Vascular Center in Nashville, TN. “I have treated over 150 patients with the AngioVac System and can attest to the clinical value of having the ability to safely remove intracardiac masses and vegetation with high procedural success and minimal blood loss or complications. With a code now available I encourage anyone using this therapy in the cardiac space to bill using 0644T so we can eventually have a Category I code.”
The AngioVac System utilizes an extracorporeal circuit and funnel-tipped, self-expanding, cannula for the removal of commonly encountered undesirable intravascular material, such as fresh, soft thrombi, emboli or vegetation in locations including but not limited to the right atrium, superior vena cava, inferior vena cava, and the iliofemoral veins. To learn more about the AngioVac System, visit AngioVac.com; see bit.ly/AVRiskInfo for risk information.
Investor Relations Contact:
About AngioDynamics, Inc.
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. For more information, visit www.angiodynamics.com.
*AngioDynamics, the AngioDynamics logo, and AngioVac are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. All other trademarks are the property of their respective owners. ©2021 AngioDynamics, Inc.
1Dr. Reddy is a paid consultant of AngioDynamics, Inc.